We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mechanism Discovered for Cancer Cell Metastasis

By LabMedica International staff writers
Posted on 18 Jul 2012
Image: Electron microscopy of a tumor cell (blue, green) on the way to extravasate through an alveolar endothelium blood capillary (purple, red). Tumor cell protrusions are seen forming their way through the endothelial cell (Photo courtesy of the University of Zurich.)
Image: Electron microscopy of a tumor cell (blue, green) on the way to extravasate through an alveolar endothelium blood capillary (purple, red). Tumor cell protrusions are seen forming their way through the endothelial cell (Photo courtesy of the University of Zurich.)
Image: Tumor cells (green) adhere on the endothelium (red) that becomes activated and permeable via CCL2-CCR2 signaling. Tumor cell extravasation is facilitated by recruited monocytic cells (blue). Technique: Adaptation of confocal image stacks creating an artificial surface. (Photo courtesy of the University of Zurich.)
Image: Tumor cells (green) adhere on the endothelium (red) that becomes activated and permeable via CCL2-CCR2 signaling. Tumor cell extravasation is facilitated by recruited monocytic cells (blue). Technique: Adaptation of confocal image stacks creating an artificial surface. (Photo courtesy of the University of Zurich.)
Scientists have for the first time discovered a mechanism by which cancer cells metastasize to other parts of the body, where they form the secondary tumors responsible for the vast majority of cancer-related deaths.

Until now, molecular level processes leading to the metastatic spread into certain organs have been unknown, it being unclear as to how the secondary cells are able to leave the bloodstream and enter the tissue of other organs. A European team of physiologists and neuropathologists, primarily through the University of Zurich (Switzerland), have now identified a biochemical pathway underlying the origin of metastasis formation whereby at least some, if not all, types of cancer cells metastasize out of the bloodstream. The team, led by principal investigators Dr. Lubor Borsig and Dr. Mathias Heikenwalder, demonstrated that intestinal cancer cells manipulate specific “doorman receptors” on the endothelium of the blood vessels.

Elevated levels of the chemokine CCL2 are known to be characteristic of metastasizing breast, prostate, and intestinal bowel types of cancer cells; clinically, high CCL2 values have been primarily taken as an indication of strong tumor growth and a poor prognosis. Increased CCL2 expression has also been correlated with recruitment of CCR2+Ly6Chi monocytes, CCR2 being a CCL2-activated receptor. Based on in vivo and in vitro experiments, the current study has now shown CCL2 to be far more than an indicator of the cancer’s aggressiveness – CCL2 was found to be part of a signal transduction mechanism critical in helping at least some types of cancer cells metastasize.

The study describes CCL2 upregulation in metastatic UICC stage IV colon carcinomas and demonstrates that tumor cell-derived CCL2 activates the CCR2+ endothelium and thereby leads to increased vascular permeability in vivo. CCR2 acts as a “doorman receptor” activated by CCL2. The role of the CCR2 doorman in a healthy organism is not known and has only now been detected on the endothelium for the first time. Dr. Borsig suspects that the doorman is involved in modulating the permeability of the blood vessels during the body’s immune response.

“The mechanism discovered will yield a completely new approach for the development of drugs to combat metastasis in breast, prostate, and bowel cancer,” Dr. Borsig is convinced. Suppressing the tumor’s chemokine expression or blocking the doorman specifically for the tumor chemokine to inhibit cancer cells from entering healthy tissue from the bloodstream is conceivable. “If we can succeed in preventing the cancer cells from leaving the bloodstream, the metastasis can be fought directly at the source,” concludes Dr. Borsig.

Related Links:

University of Zurich





New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Serological Pipet Controller
PIPETBOY GENIUS
New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
New
Modular Hemostasis Automation Solution
CN Track

DIASOURCE (A Biovendor Company)

Channels

Molecular Diagnostics

view channel
Image: The RNA-seq based diagnostic test for pediatric leukemia ensures better outcomes for children with this common cancer (Photo courtesy of Qlucore)

RNA-Seq Based Diagnostic Test Enhances Diagnostic Accuracy of Pediatric Leukemia

A new unique test is set to reshape the way Acute Lymphoblastic Leukemia (BCP-ALL) samples can be analyzed. Qlucore (Lund, Sweden) has launched the first CE-marked RNA-seq based diagnostic test for pediatric... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
PURITAN MEDICAL